Lyra Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Lyra Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2023.
  • Lyra Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$48.1M, a 208% decline year-over-year.
  • Lyra Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$101M, a 66.6% decline year-over-year.
  • Lyra Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$62.7M, a 13.4% decline from 2022.
  • Lyra Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$55.3M, a 27% decline from 2021.
  • Lyra Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$43.5M, a 96.7% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$62.7M -$7.4M -13.4% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-22
2022 -$55.3M -$11.8M -27% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-22
2021 -$43.5M -$21.4M -96.7% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-29
2020 -$22.1M -$5.82M -35.7% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-09
2019 -$16.3M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.